Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in refractory focal epilepsy
NCT05613166Phase 2Unknown
- Sponsor
- National Institute on Drug Dependence
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in Focal Epilepsy (FE), sponsored by National Institute on Drug Dependence. Status: unknown.
02
Drugs
everolimus
03
Conditions
Focal Epilepsy (FE)
Beyond the preview
Go deeper on NCT05613166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613166.